Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Rob Hutchison Obituary
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(325)
•••
Comment by TheTruth1234on Apr 06, 2024 3:04pm
128 Views
Post# 35974983

RE:Rob Hutchison Obituary

RE:Rob Hutchison Obituary
InitiumMMXXIII wrote: Rob Hutchison passed away on November 24, 2023. I heard about it a couple of days before Christmas, but because I couldn't find a supporting document at that time, I didn't want to post the news. I did a search yesterday and found Rob's obituary in the Vancouver Sun/The Province obits section. It was posted there on December 1, 2023. My earlier search either didn't turn it up or I missed it.

In any event, it's sad news. He and Bioasis played a big part in my life. and many of yours,  for many years.

My condolences to his family and friends.

jd



He and Bioasis played a big part in my life. and many of yours, for many years.

Yes, Johnny boy.  You two kept the Bioasis sca....  cough cough story going for many years!!

Congratulations!!

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities